Ignite Creation Date:
2024-05-06 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04702503
Status:
COMPLETED
Last Update Posted:
2021-01-11
First Post:
2019-03-19
Brief Title:
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma CTCL
Sponsor:
Moleculin Biotech Inc
Organization:
Moleculin Biotech Inc
Study Overview
Official Title:
A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220 an Inhibitor of STAT3 Activation in Adults With Stage I II or III Mycosis Fungoides Cutaneous T-Cell Lymphoma CTCL
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Single center pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I II or III Mycosis Fungoides CTCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None